These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 20405274

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Anticancer Effect of Ursodeoxycholic Acid in Human Oral Squamous Carcinoma HSC-3 Cells through the Caspases.
    Pang L, Zhao X, Liu W, Deng J, Tan X, Qiu L.
    Nutrients; 2015 May 05; 7(5):3200-18. PubMed ID: 25951128
    [Abstract] [Full Text] [Related]

  • 25. Chitosan-stabilized selenium nanoparticles alleviate cardio-hepatic damage in type 2 diabetes mellitus model via regulation of caspase, Bax/Bcl-2, and Fas/FasL-pathway.
    Mohamed AA, Khater SI, Hamed Arisha A, Metwally MMM, Mostafa-Hedeab G, El-Shetry ES.
    Gene; 2021 Feb 05; 768():145288. PubMed ID: 33181259
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Hepatobiliary complications in healthy, intra-abdominally infected, and high-output fistula rats receiving total parenteral nutrition.
    Mok KT.
    JPEN J Parenter Enteral Nutr; 1993 Feb 05; 17(5):449-53. PubMed ID: 8289412
    [Abstract] [Full Text] [Related]

  • 28. Reduction of hepatocarcinogenesis by ursodeoxycholic acid in rats.
    Oyama K, Shiota G, Ito H, Murawaki Y, Kawasaki H.
    Carcinogenesis; 2002 May 05; 23(5):885-92. PubMed ID: 12016164
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. A possible beneficial effect of metronidazole in reducing TPN-associated liver function derangements.
    Freund HR, Muggia-Sullam M, LaFrance R, Enrione EB, Popp MB, Bjornson HS.
    J Surg Res; 1985 Apr 05; 38(4):356-63. PubMed ID: 3923267
    [Abstract] [Full Text] [Related]

  • 34. Dose variation of hepatocyte growth factor and its effects on an animal model of TPN-induced liver injury.
    Katz MS, Thatch KA, Schwartz MZ.
    J Surg Res; 2010 Oct 05; 163(2):294-8. PubMed ID: 20691983
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Growth factor modulation of hepatic inflammation: a novel approach to the management of total parenteral nutrition-associated liver disease.
    Thatch KA, Katz MS, Haber MM, Schwartz MZ.
    J Pediatr Surg; 2010 Jan 05; 45(1):89-94. PubMed ID: 20105586
    [Abstract] [Full Text] [Related]

  • 37. Investigation of parenteral nutrition-induced hepatotoxicity using human liver spheroid co-cultures.
    Mihajlovic M, De Boever S, Tabernilla A, Callewaert E, Sanz-Serrano J, Verhoeven A, Maerten A, Rosseel Z, De Waele E, Vinken M.
    Arch Toxicol; 2024 Sep 05; 98(9):3109-3126. PubMed ID: 38740588
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Early use of cyclic TPN prevents further deterioration of liver functions for the TPN patients with impaired liver function.
    Hwang TL, Lue MC, Chen LL.
    Hepatogastroenterology; 2000 Sep 05; 47(35):1347-50. PubMed ID: 11100349
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.